Brief: CERo Therapeutics Advances Phase 1 CER-1236 Trial with Dose Intensification in AML
08/09/2025 13:56
Sept 8 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS ANNOUNCES DOSE INTENSIFICATION IN PHASE 1 STUDY OF CER-1236 IN ACUTE MYELOID LEUKEMIA Source text: ID:nGNX7fS7Lc Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List